None of the 17 subjects in the 2015 study experienced VTE events, despite a VTE prophylaxis algorithm identical to ours, thus raising the question of whether the high VTE risk in our study was a disease‐specific concern unique to anti‐MAG neuropathy patients. This evidence concerns the gene MAG and neuropathy.